Branch retinal vein occlusion post severe acute respiratory syndrome coronavirus 2 vaccination
In this article, we report two patients who experienced the first onset of branch retinal vein occlusion (BRVO) 3 days after the administration of the BNT162b2 (Pfizer–BioNTech) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. Case 1: A 50-year-old woman without any history of r...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
| Series: | Taiwan Journal of Ophthalmology |
| Subjects: | |
| Online Access: | http://www.e-tjo.org/article.asp?issn=2211-5056;year=2022;volume=12;issue=2;spage=202;epage=205;aulast=Tanaka |
| _version_ | 1818196442203815936 |
|---|---|
| author | Hayato Tanaka Daisuke Nagasato Shunsuke Nakakura Toshihiko Nagasawa Hiroyuki Wakuda Akihiro Kurusu Yoshinori Mitamura Hitoshi Tabuchi |
| author_facet | Hayato Tanaka Daisuke Nagasato Shunsuke Nakakura Toshihiko Nagasawa Hiroyuki Wakuda Akihiro Kurusu Yoshinori Mitamura Hitoshi Tabuchi |
| author_sort | Hayato Tanaka |
| collection | DOAJ |
| description | In this article, we report two patients who experienced the first onset of branch retinal vein occlusion (BRVO) 3 days after the administration of the BNT162b2 (Pfizer–BioNTech) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. Case 1: A 50-year-old woman without any history of retinal disease developed vision loss in her right eye 3 days after receiving the first dose of the SARS-CoV-2 mRNA vaccine. Case 2: A 56-year-old woman without any history of retinal disease developed vision loss in her right eye 3 days after receiving the first dose of the SARS-CoV-2 mRNA vaccine. Case 1: Temporal superior BRVO and secondary macular edema (ME) were observed in the patient's right eye. Her best-corrected visual acuity (BCVA) was 20/25. Case 2: Temporal inferior BRVO and secondary ME were observed in the patient's right eye. Her BCVA was 13/20. Case 1: Three doses of intravitreal ranibizumab (IVR) were administered. Case 2: Three doses of IVR were administered. Case 1: ME resolved and BCVA improved to 20/20. Case 2: ME resolved and BCVA improved to 20/20. Both the cases showed a possible association between the SARS-CoV-2 vaccination and the first onset of BRVO. |
| first_indexed | 2024-12-12T01:34:09Z |
| format | Article |
| id | doaj.art-7396b22941fa43b6899dda6a308b49f2 |
| institution | Directory Open Access Journal |
| issn | 2211-5056 2211-5072 |
| language | English |
| last_indexed | 2024-12-12T01:34:09Z |
| publishDate | 2022-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Taiwan Journal of Ophthalmology |
| spelling | doaj.art-7396b22941fa43b6899dda6a308b49f22022-12-22T00:42:52ZengWolters Kluwer Medknow PublicationsTaiwan Journal of Ophthalmology2211-50562211-50722022-01-0112220220510.4103/tjo.tjo_24_22Branch retinal vein occlusion post severe acute respiratory syndrome coronavirus 2 vaccinationHayato TanakaDaisuke NagasatoShunsuke NakakuraToshihiko NagasawaHiroyuki WakudaAkihiro KurusuYoshinori MitamuraHitoshi TabuchiIn this article, we report two patients who experienced the first onset of branch retinal vein occlusion (BRVO) 3 days after the administration of the BNT162b2 (Pfizer–BioNTech) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. Case 1: A 50-year-old woman without any history of retinal disease developed vision loss in her right eye 3 days after receiving the first dose of the SARS-CoV-2 mRNA vaccine. Case 2: A 56-year-old woman without any history of retinal disease developed vision loss in her right eye 3 days after receiving the first dose of the SARS-CoV-2 mRNA vaccine. Case 1: Temporal superior BRVO and secondary macular edema (ME) were observed in the patient's right eye. Her best-corrected visual acuity (BCVA) was 20/25. Case 2: Temporal inferior BRVO and secondary ME were observed in the patient's right eye. Her BCVA was 13/20. Case 1: Three doses of intravitreal ranibizumab (IVR) were administered. Case 2: Three doses of IVR were administered. Case 1: ME resolved and BCVA improved to 20/20. Case 2: ME resolved and BCVA improved to 20/20. Both the cases showed a possible association between the SARS-CoV-2 vaccination and the first onset of BRVO.http://www.e-tjo.org/article.asp?issn=2211-5056;year=2022;volume=12;issue=2;spage=202;epage=205;aulast=Tanakaadverse reactionsbranch retinal vein occlusioncoronavirus disease 2019vaccination |
| spellingShingle | Hayato Tanaka Daisuke Nagasato Shunsuke Nakakura Toshihiko Nagasawa Hiroyuki Wakuda Akihiro Kurusu Yoshinori Mitamura Hitoshi Tabuchi Branch retinal vein occlusion post severe acute respiratory syndrome coronavirus 2 vaccination Taiwan Journal of Ophthalmology adverse reactions branch retinal vein occlusion coronavirus disease 2019 vaccination |
| title | Branch retinal vein occlusion post severe acute respiratory syndrome coronavirus 2 vaccination |
| title_full | Branch retinal vein occlusion post severe acute respiratory syndrome coronavirus 2 vaccination |
| title_fullStr | Branch retinal vein occlusion post severe acute respiratory syndrome coronavirus 2 vaccination |
| title_full_unstemmed | Branch retinal vein occlusion post severe acute respiratory syndrome coronavirus 2 vaccination |
| title_short | Branch retinal vein occlusion post severe acute respiratory syndrome coronavirus 2 vaccination |
| title_sort | branch retinal vein occlusion post severe acute respiratory syndrome coronavirus 2 vaccination |
| topic | adverse reactions branch retinal vein occlusion coronavirus disease 2019 vaccination |
| url | http://www.e-tjo.org/article.asp?issn=2211-5056;year=2022;volume=12;issue=2;spage=202;epage=205;aulast=Tanaka |
| work_keys_str_mv | AT hayatotanaka branchretinalveinocclusionpostsevereacuterespiratorysyndromecoronavirus2vaccination AT daisukenagasato branchretinalveinocclusionpostsevereacuterespiratorysyndromecoronavirus2vaccination AT shunsukenakakura branchretinalveinocclusionpostsevereacuterespiratorysyndromecoronavirus2vaccination AT toshihikonagasawa branchretinalveinocclusionpostsevereacuterespiratorysyndromecoronavirus2vaccination AT hiroyukiwakuda branchretinalveinocclusionpostsevereacuterespiratorysyndromecoronavirus2vaccination AT akihirokurusu branchretinalveinocclusionpostsevereacuterespiratorysyndromecoronavirus2vaccination AT yoshinorimitamura branchretinalveinocclusionpostsevereacuterespiratorysyndromecoronavirus2vaccination AT hitoshitabuchi branchretinalveinocclusionpostsevereacuterespiratorysyndromecoronavirus2vaccination |